Search research articles
Contact Us
Filters
Showing results (61-70 of 64) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 64 results.
Diabetes, Obesity & Metabolism
|
August 1, 2019
A novel specific peroxisome proliferator-activated receptor γ (PPARγ) modulator YR4-42 ameliorates hyperglycaemia and dyslipidaemia and hepatic steatosis in diet-induced obese mice
Yi Huan, Xuan Pan, Jun Peng, et al.
Scientific Reports
|
June 30, 2017
The dual DPP4 inhibitor and GPR119 agonist HBK001 regulates glycemic control and beta cell function ex and in vivo
Yi Huan, Qian Jiang, Gang Li, et al.
Fluids and Barriers of the CNS
|
April 17, 2024
Choroid plexus enlargement in amyotrophic lateral sclerosis patients and its correlation with clinical disability and blood-CSF barrier permeability
Tingjun Dai, Jianwei Lou, Deyuan Kong, et al.
Biochemical Pharmacology
|
January 23, 2018
Glutazumab, a novel long-lasting GLP-1/anti-GLP-1R antibody fusion protein, exerts anti-diabetic effects through targeting dual receptor binding sites
Caina Li, Miaomiao Yang, Xiaofeng Wang, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 64) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 64 results.
Diabetes, Obesity & Metabolism
|
August 1, 2019
A novel specific peroxisome proliferator-activated receptor γ (PPARγ) modulator YR4-42 ameliorates hyperglycaemia and dyslipidaemia and hepatic steatosis in diet-induced obese mice
Yi Huan, Xuan Pan, Jun Peng, et al.
Scientific Reports
|
June 30, 2017
The dual DPP4 inhibitor and GPR119 agonist HBK001 regulates glycemic control and beta cell function ex and in vivo
Yi Huan, Qian Jiang, Gang Li, et al.
Fluids and Barriers of the CNS
|
April 17, 2024
Choroid plexus enlargement in amyotrophic lateral sclerosis patients and its correlation with clinical disability and blood-CSF barrier permeability
Tingjun Dai, Jianwei Lou, Deyuan Kong, et al.
Biochemical Pharmacology
|
January 23, 2018
Glutazumab, a novel long-lasting GLP-1/anti-GLP-1R antibody fusion protein, exerts anti-diabetic effects through targeting dual receptor binding sites
Caina Li, Miaomiao Yang, Xiaofeng Wang, et al.
Page
of 7